Opendata, web and dolomites

GAF SIGNED

The First non-cancerogenic Glyoxal Acid-Free fixative for a Formalin-free hospital

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 GAF project word cloud

Explore the words cloud of the GAF project. It provides you a very rough idea of what is the project "GAF" about.

addressable    veterinary    toxicity    university    initially    updated    forensic    represented    clinics    performing    gaf    formaldehyde    pathological    accepted    glyoxal    union    2017    laboratories    preserving    acid    customers    primarily    torino    investments    replace    agreements    commercialization    time    community    market    pharmaceutical    optimal    correct    reagent    first    chemical    finance    introducing    institutes    cros    scientific    free    specimens    medical    clients    producers    feasibility    retain    model    plan    august    scenario    business    biosciences    healthcare    academic    addax    alternative    private    founders    serve    hospitals    substance    company    faster    capacity    proposes    fixation    validate    second    cancerogenic    combined    born    solution    fixative    huge    spin    services    preserve    off    segment    pathology    guarantee    patient    proof    innovative    formalin    prohibited    tissues    valid    carcinogenic    emergency    therapy    molecular    diagnostic    public    diagnosis    quality    phases    outsourcing    labs    absence    tissue    entities    structural   

Project "GAF" data sheet

The following table provides information about the project.

Coordinator
ADDAX BIOSCIENCES SRL 

Organization address
address: STRADA MONTGRENO 247
city: TORINO
postcode: 10123
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2020
 Duration (year-month-day) from 2020-01-01   to  2020-06-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ADDAX BIOSCIENCES SRL IT (TORINO) coordinator 50˙000.00

Map

 Project objective

ADDAX Biosciences is an academic spin-off of the University of Torino, born after long time research activity of its founders on the pathological tissues. Our company goal is to replace the use of Formalin (a cancerogenic solution of formaldehyde) as fixative, while preserving optimal tissue fixation to guarantee correct diagnosis and therapy. In the European Union, Formaldehyde is recognized as a carcinogenic substance, and its use, production and commercialization is prohibited from August 2017. However, at present there is no valid alternative to Formalin accepted by the scientific community to preserve patient specimens. Our project proposes a huge step forward in the fixative market by introducing an innovative reagent, based on acid-free Glyoxal (GAF), that will allow the optimal tissue fixation at structural and molecular level, combined with the absence of toxicity and carcinogenic activity. The addressable market of our GAF product is primarily represented by the healthcare segment, thus the targeted users and clients are public and private entities performing pathology services, such as: Hospitals, Clinics, Emergency Medical Services, Diagnostic Laboratories, Academic Institutes, Forensic Laboratories, CROs, Veterinary Clinics, Labs and Hospitals. Our business model is initially based in two distinct phases: the first one aimed to achieve a controlled production capacity to serve the first customers and finance the further investments; in the second phase, from second year, we expect a faster scale-up through outsourcing production agreements with major European producers of chemical and pharmaceutical products. In this scenario, Addax will retain the R&D, quality, scientific and market development. The objectives of our Feasibility Study are to validate at European level our proof-of-concept and design an updated Business Plan and Commercialization Plan.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "GAF" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "GAF" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

COPI (2020)

Carbon Offset Plug-in

Read More  

Magnesys (2019)

Efficient filtering of metallic impurities in food processing

Read More  

LIVELMIA (2019)

Innovative assay for microRNAs analysis

Read More